Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 441-450 of 639 results
Frontiers in Pharmacology, 2022 • March 31, 2022
This study investigated the therapeutic potential of SHED-CM for neuropathic pain (NP) using a mouse model of partial sciatic nerve ligation (PSL). The results showed that SHED-CM effectively reduced ...
KEY FINDING: Intravenous administration of SHED-CM greatly improved PSL-induced hypersensitivity, indicating a reduction in neuropathic pain symptoms in mice.
Exp Neurol, 2022 • September 1, 2022
This study investigates a therapeutic strategy co-targeting kinases involved in extrinsic and intrinsic regulatory pathways to promote axon regeneration after spinal cord injury (SCI). The kinase inhi...
KEY FINDING: RO48 promotes neurite growth from various neuronal types in vitro, including hippocampal, cortical, sensory, and human iPSC-derived glutamatergic neurons.
Biotechnology Advances, 2022 • May 16, 2022
Extracellular vesicles (EVs), particularly exosomes, hold promise for treating various diseases and promoting tissue regeneration. However, current production methods suffer from low yield and scalabi...
KEY FINDING: Mechanical loading, such as shear stress or cyclic tension, can significantly increase EV secretion, potentially by over 100-fold.
Neurotherapeutics, 2022 • May 20, 2022
This study investigates the therapeutic potential of activating BDNF/TrkB signaling and inhibiting δ-secretase in a mouse model of Parkinson's Disease (PD). The researchers used CF3CN, a TrkB agonist...
KEY FINDING: CF3CN activates the TrkB-mediated neurotrophic pathway and decreases α-Syn N103 cleavage, while #11A strongly blocks δ-secretase and reduces α-Syn N103 fragmentation, leading to increased dopaminergic neurons.
Frontiers in Cellular Neuroscience, 2022 • May 4, 2022
This study investigated the therapeutic potential of ursolic acid (UA) in treating spinal cord injury (SCI) in mice, focusing on its impact on gut microbiota and metabolic changes. The research demons...
KEY FINDING: UA treatment increased body weight and soleus muscle weight of SCI mice, suggesting improved motor function.
Pharmaceuticals, 2022 • April 25, 2022
This study investigates the regulatory action of miR-182-5p on Nogo-A, a myelin-associated inhibitor of axonal regeneration. The research demonstrates that miR-182-5p downregulates Nogo-A protein expr...
KEY FINDING: miR-182-5p mimic specifically downregulates the expression of the luciferase reporter gene fused to the mouse Nogo-A 3′UTR, and Nogo-A protein expression in Neuro-2a and C6 cells.
Neurospine, 2022 • June 1, 2022
This review article discusses established management strategies and emerging therapeutic approaches for acute spinal cord injury (SCI). It emphasizes the importance of early surgical decompression and...
KEY FINDING: Early surgical decompression (within 24 hours) is associated with better neurological recovery and shorter hospital stays.
Neural Regeneration Research, 2023 • January 1, 2023
Central axons fail to regenerate appropriately after a traumatic lesion. Therefore, the damaged connections are not reestablished after SCI, leaving permanent dysfunctions. Among several therapeutic i...
KEY FINDING: Molecular compounds, including drugs, growth factors, enzymes, and purines, are being explored in preclinical and clinical studies to treat spinal cord injuries.
Clinical and Translational Medicine, 2022 • June 20, 2022
This study demonstrates that AZD1390, an orally bioavailable, brain-penetrant, potent, and highly selective inhibitor of ataxia–telangiectasia mutated (ATM), promotes dramatic recovery after spinal co...
KEY FINDING: Oral AZD1390 significantly suppresses pATM levels in dorsal root ganglia (DRG) at 4 weeks after DC injury.
Biomedicines, 2022 • July 12, 2022
Spinal cord injury (SCI) results from initial physical trauma followed by secondary injury, leading to neural degeneration and locomotor performance loss. Current treatments face limitations due to th...
KEY FINDING: SCI's physiopathology is an extremely disabling disease that heavily affects the life of the patients and is the result of a primary injury that is then followed by a secondary one, commonly known as the main cause of post-traumatic neural degeneration.